"The Mission of HOA is to provide the highest level of quality care in a healing environment for the mind, body and spirit of patients dealing with cancer and blood disorders. Our goal is to offer the highest level, state of the art technology and treatments, while meeting the emotional needs of our patients and their families."

During the past decade, Hematology Oncology Associates of Central New York-East Syracuse conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 58 clinical trials were completed, i.e. on average, 118.4% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 29 clinical trials were completed. i.e. 116% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology Oncology Associates of Central New York-East Syracuse" #1 sponsor was "National Cancer Institute (NCI)" with 56 trials, followed by "Alliance for Clinical Trials in Oncology" with 18 trials sponsored, "SWOG Cancer Research Network" with 7 trials sponsored, "Academic and Community Cancer Research United" with 4 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 4 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology Oncology Associates of Central New York-East Syracuse" #1 collaborator was "National Cancer Institute (NCI)" with 41 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "Cancer and Leukemia Group B" with 5 trials as a collaborator, "SWOG Cancer Research Network" with 5 trials as a collaborator and "Canadian Cancer Trials Group" with 4 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Hematology Oncology Associates of Central New York-East Syracuse" are "Breast Cancer" (9 trials), "Stage IV Breast Cancer AJCC v6 and v7" (9 trials), "Invasive Breast Carcinoma" (8 trials), "HER2/Neu Negative" (7 trials) and "Recurrent Breast Carcinoma" (7 trials). Many other conditions were trialed in "Hematology Oncology Associates of Central New York-East Syracuse" in a lesser frequency.

Most popular intervention types in "Hematology Oncology Associates of Central New York-East Syracuse" are "Drug" (85 trials), "Other" (82 trials), "Biological" (42 trials), "Procedure" (22 trials) and "Radiation" (9 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Quality-of-Life Assessment" (34 trials), "Questionnaire Administration" (18 trials), "Bevacizumab" (16 trials) and "Paclitaxel" (16 trials). Other intervention names were less common.

The vast majority of trials in "Hematology Oncology Associates of Central New York-East Syracuse" are 93 trials for "All" genders, 14 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hematology Oncology Associates of Central New York-East Syracuse". undefined are not yet recruiting, 22 are recruiting, 42 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 38 completed trials in Hematology Oncology Associates of Central New York-East Syracuse, 2 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology Oncology Associates of Central New York-East Syracuse, 3 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".